• MeSH
• Chemotherapy, Adjuvant MeSH
• Contraception contraindications   MeSH
• Goserelin administration & dosage   pharmacokinetics   contraindications   adverse effects   therapeutic use   MeSH
• Gonadotropin-Releasing Hormone agonists   pharmacokinetics   adverse effects   therapeutic use   MeSH
• Antineoplastic Agents, Hormonal administration & dosage   pharmacokinetics   adverse effects   therapeutic use   MeSH
• Injections, Subcutaneous MeSH
• Meta-Analysis as Topic MeSH
• Premenopause MeSH
• Tamoxifen administration & dosage   pharmacokinetics   adverse effects   therapeutic use   MeSH
• Publication type
• Review MeSH

• Conspectus
• Farmacie. Farmakologie
• NML Fields
• farmacie a farmakologie
• onkologie
• gynekologie a porodnictví

• MeSH
• Adult MeSH
• Goserelin * pharmacology   therapeutic use   MeSH
• Organ Sparing Treatments methods   MeSH
• Humans MeSH
• Breast Neoplasms * drug therapy   genetics   MeSH
• Antineoplastic Combined Chemotherapy Protocols * adverse effects   therapeutic use   MeSH
• Fertility Preservation * methods   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Female MeSH
• Publication type
• Controlled Clinical Trial MeSH
• Newspaper Article MeSH

• MeSH
• Adult MeSH
• Goserelin * pharmacology   therapeutic use   MeSH
• Organ Sparing Treatments * methods   MeSH
• Humans MeSH
• Adolescent MeSH
• Breast Neoplasms * drug therapy   MeSH
• Primary Ovarian Insufficiency chemically induced   prevention & control   MeSH
• Antineoplastic Combined Chemotherapy Protocols * adverse effects   therapeutic use   MeSH
• Triple Negative Breast Neoplasms * drug therapy   MeSH
• Fertility Preservation * methods   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Adolescent MeSH
• Female MeSH
• Publication type
• Controlled Clinical Trial MeSH
• Newspaper Article MeSH

Pánevní kongesce je zvláštní forma chronického žilního onemocnění postihující ženy. Definovaná je jako klinicko‑anatomický syndrom charakterizovaný chronickou pánevní bolestí, perineálním dyskomfortem, mikčními obtížemi a postkoitální bolestí, které jsou způsobeny ovariálním a/nebo pánevním žilním refluxem. Bývá příčinou varixů vulvy, perinea, hýždí a dolních končetin. Těsný vztah je mezi symptomatickými pánevními varixy a renálním syndromem louskáčku. Duplexní ultrasonografie žil břicha, pánve, dolních končetin a vulvoperineální oblasti je hlavní neinvazivní dia­gnostickou metodou. Magnetická rezonanční venografie nebo jen MR venografie má vysokou senzitivitu v hodnocení pánevní kongesce a může být užita jako screeningové vyšetření nebo v případě nejasného nálezu na ultrazvuku a klinických pochybností. Možnosti medikamentózní terapie jsou omezené, základními léky jsou venofarmaka. Endovaskulární intervence – terapeutická embolizace ovariálních/pánevních žil a implantace ilikokaválního a renálního endovenózního stentu – se stává léčbou první volby u žen s těžkými příznaky, které nereagují na konzervativní terapii.

Pelvic congestion is a special form of chronic venous disease in women. This is defined as s syndrome which includes chronic pelvic pain, perineal discomfort, difficulties of micturition, and post‑coital pain in association with ovarian and/or pelvic vein reflux. It may cause vulvar, perineal, gluteal and lower extremity varices. There is a close relation between symptomatic pelvic varices and renal nutcracker syndrome. Duplex ultrasound of abdominal, pelvic and lower extrem­ity veins and vulvoprineal region is the cardinal method of non‑invasive examination. MRI Venography is a highly sensitive technique for evaluating pelvic congestion. It may be used as a screening method or in cases of ambiguous sonographic findings and doubts. Pharmaceutical treatment options are limited, and therapy is based on venoactive drugs. Endovascular intervention – ovarian/iliac veins embolisation therapy and ilio‑caval and renal venous stenting – becomes the first line of treatment for women with severe symptoms, which are resistant to conservative approaches.

• MeSH
• Diagnosis, Differential MeSH
• Endovascular Procedures utilization   MeSH
• Phlebography methods   MeSH
• Goserelin MeSH
• Humans MeSH
• Medroxyprogesterone Acetate MeSH
• Vascular Diseases diagnosis   classification   therapy   ultrasonography   MeSH
• Ovary blood supply   MeSH
• Pelvis * blood supply   MeSH
• Pelvic Pain * diagnosis   etiology   therapy   MeSH
• Gonadal Hormones MeSH
• Embolization, Therapeutic MeSH
• Varicose Veins * diagnosis   epidemiology   etiology   pathology   MeSH
• Genitalia, Female * blood supply   MeSH
• Venous Insufficiency diagnosis   therapy   MeSH
• Check Tag
• Humans MeSH
• Female MeSH
• Publication type
• Review MeSH

• MeSH
• Survival Analysis MeSH
• Biological Therapy MeSH
• Genes, BRCA1 drug effects   MeSH
• Goserelin therapeutic use   MeSH
• Congresses as Topic MeSH
• Medical Oncology * MeSH
• Humans MeSH
• Breast Neoplasms drug therapy   genetics   MeSH
• Neoadjuvant Therapy methods   MeSH
• Ovariectomy methods   MeSH
• Ovary drug effects   MeSH
• Premenopause MeSH
• Check Tag
• Humans MeSH
• Female MeSH
• Publication type
• Controlled Clinical Trial MeSH

• MeSH
• Chemotherapy, Adjuvant methods   MeSH
• Quinazolines therapeutic use   MeSH
• Molecular Targeted Therapy methods   MeSH
• Goserelin therapeutic use   MeSH
• Protein Kinase Inhibitors therapeutic use   MeSH
• Colorectal Neoplasms * drug therapy   genetics   MeSH
• Humans MeSH
• Neoplasm Metastasis * drug therapy   MeSH
• Survival Rate MeSH
• Antibodies, Monoclonal therapeutic use   MeSH
• Prostatic Neoplasms drug therapy   MeSH
• Breast Neoplasms drug therapy   genetics   MeSH
• Stomach Neoplasms drug therapy   MeSH
• Neoplasms, Hormone-Dependent drug therapy   MeSH
• Carcinoma, Non-Small-Cell Lung drug therapy   MeSH
• Neoadjuvant Therapy methods   MeSH
• Premenopause MeSH
• Disease-Free Survival MeSH
• Antineoplastic Combined Chemotherapy Protocols * therapeutic use   MeSH
• Vascular Endothelial Growth Factor Receptor-2 antagonists & inhibitors   MeSH
• Neoplasm Staging MeSH
• Tamoxifen therapeutic use   MeSH
• Taxoids therapeutic use   MeSH
• Treatment Outcome MeSH
• Check Tag
• Humans MeSH
• Publication type
• Clinical Trial MeSH
• Review MeSH

• MeSH
• Survival Analysis MeSH
• Androstenols therapeutic use   MeSH
• Goserelin therapeutic use   MeSH
• Humans MeSH
• Neoplasm Metastasis drug therapy   pathology   MeSH
• Bone Neoplasms radiotherapy   secondary   MeSH
• Prostatic Neoplasms, Castration-Resistant drug therapy   MeSH
• Prostatic Neoplasms * drug therapy   pathology   MeSH
• Taxoids therapeutic use   MeSH
• Check Tag
• Humans MeSH

Autoři v předloženém textu referují o souboru pěti pacientek s diagnostikovanou endometriózou močového traktu. U čtyř nemocných se jednalo o postižení močového měchýře, u jedné pacientky o lokalizaci v ureteru. Autoři poukazují na nutnost důkladného vyšetření a zhodnocení nespecifických symptomů, které jsou typické pro endometriózu močového systému. Základní léčba je chirurgická, v případě recidivy bývá doplněna o léčbu kastrační, a to buď podáním LHRH-agonistů, či danazolu.

Authors in submitted text report five patients diagnosed with endometriosis of the urinary tract. In four patients we observed involvement of the bladder, in one patient localization of the left ureter. The authors point out necessity of thorough examination and evaluation of nonspecific symptoms that are typical of endometriosis of the urinary tract. Gold standard of treatment is surgical treatment, which is followed in the case of recurrence by castration therapy by either danazol or LHRH administration.

• Keywords
• transuretrální resekce, LHRH,
• MeSH
• Danazol therapeutic use   MeSH
• Adult MeSH
• Endometriosis * diagnosis   classification   therapy   MeSH
• Goserelin therapeutic use   MeSH
• Gonadotropin-Releasing Hormone therapeutic use   MeSH
• Humans MeSH
• Minimally Invasive Surgical Procedures MeSH
• Young Adult MeSH
• Urinary Tract pathology   MeSH
• Urinary Bladder * surgery   pathology   MeSH
• Recurrence MeSH
• Ureter * surgery   pathology   MeSH
• Urologic Surgical Procedures MeSH
• Urologic Diseases diagnosis   physiopathology   therapy   MeSH
• Check Tag
• Adult MeSH
• Humans MeSH
• Young Adult MeSH
• Female MeSH

Současné možnosti hormonální léčby karcinomu prsu jsou poměrně rozsáhlé. Existuje celá řada možných variant léčebných sekvencí, z nichž většina je již dobře ověřena dlouhou dobou sledování v jednotlivých studiích a vlastní klinickou praxí. Přesto se stále diskutuje několik témat, např. jak dlouho má trvat endokrinní léčba jako taková (koncept 5 let se zdá překonaný a na základě nejnovějších studií lze předpokládat spíše 10 let podávání). Stále častěji je diskutována problematika vzniku rezistence a nejvhodnější doby pro zařazení AI (strategie upfront nebo switch). Postupem času se rovněž v klinické praxi ukazuje, že účinnost AI je prakticky shodná, a bude tomu tak nejspíše ve všech podáních, včetně neoadjuvance a prodloužené adjuvance, přestože data u některých nebudou dostupná.

The range of options available for breast cancer hormonal therapy today is rather extensive. There are a number of therapeutic sequence variants most of which have been established in both longitudinal follow up in clinical trials and clinical practice. Debate is still ongoing, however, in several areas, e.g. regarding the desired duration of endocrine treatment in general (the conception of 5 years seems to belong to the past, and one can most likely anticipate 10 year duration based on the most recent studies). The issues of resistance development and most appropriate timing for the inclusion of aromatase inhibitors (AIs) is being discussed with increasing frequency (upfront or switch strategy). Gradually, a growing body of evidence from clinical practice show that the efficacy of various AIs is more or less identical, and this is likely to be the case in all administration modes including neodjuvant and extended adjuvant treatments, though the data must not be available for some of them.

• MeSH
• Androstadienes therapeutic use   MeSH
• Estrogen Antagonists therapeutic use   MeSH
• Adult MeSH
• Goserelin therapeutic use   MeSH
• Drug Evaluation MeSH
• Gonadotropin-Releasing Hormone agonists   therapeutic use   MeSH
• Antineoplastic Agents, Hormonal * MeSH
• Hormone Replacement Therapy MeSH
• Aromatase Inhibitors * administration & dosage   pharmacokinetics   therapeutic use   MeSH
• Clinical Trials as Topic MeSH
• Contraceptives, Oral, Hormonal MeSH
• Middle Aged MeSH
• Humans MeSH
• Meta-Analysis as Topic MeSH
• Young Adult MeSH
• Estrogen Receptor Modulators MeSH
• Breast Neoplasms * drug therapy   MeSH
• Nitriles therapeutic use   MeSH
• Antineoplastic Combined Chemotherapy Protocols MeSH
• Medication Reconciliation * MeSH
• Aged MeSH
• Tamoxifen therapeutic use   MeSH
• Triazoles therapeutic use   MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Young Adult MeSH
• Aged MeSH
• Female MeSH

• MeSH
• Survival Analysis MeSH
• Anilides administration & dosage   pharmacology   therapeutic use   MeSH
• Quinazolines administration & dosage   pharmacology   therapeutic use   MeSH
• Deoxycytidine administration & dosage   pharmacology   therapeutic use   MeSH
• Fluorouracil analogs & derivatives   pharmacology   therapeutic use   MeSH
• Goserelin administration & dosage   pharmacology   therapeutic use   MeSH
• Clinical Trials, Phase III as Topic MeSH
• Congresses as Topic MeSH
• Longitudinal Studies MeSH
• Neoplasm Metastasis drug therapy   therapy   MeSH
• Antibodies, Monoclonal administration & dosage   pharmacology   therapeutic use   MeSH
• Prostatic Neoplasms drug therapy   secretion   therapy   MeSH
• Breast Neoplasms drug therapy   secretion   therapy   MeSH
• Nitriles administration & dosage   pharmacology   therapeutic use   MeSH
• Tosyl Compounds administration & dosage   pharmacology   therapeutic use   MeSH
• Treatment Outcome MeSH
• Publication type
• Newspaper Article MeSH